Meningitis B Vaccine London: Private Doctor-Led Vaccination at The Wellness
Medically reviewed by The Online GP by The Wellness Medical Team
Last updated: 18 March 2026
The meningitis B vaccine (Bexsero) is available privately at The Wellness London from £195 per dose, administered by GMC-registered doctors at our Marylebone clinic. A full course requires two doses given at least one month apart. Following the unprecedented Kent meningitis outbreak in March 2026, demand for the MenB vaccine has surged across the UK, and national supply is extremely limited. Contact us to check current availability — stock is not guaranteed and is allocated on a first-come, first-served basis.
Check Vaccine Availability on WhatsApp →
Alternatively, email us at team@thewellnesslondon.com to register your interest.
Why Choose The Wellness for Your Meningitis B Vaccine
The Wellness London is a private healthcare group led by GMC-registered doctors, providing a level of medical oversight that goes well beyond what high-street pharmacies can offer. When you receive your meningitis B vaccination with us, the entire process is managed by a qualified doctor — not a pharmacist or nurse.
This matters because meningococcal vaccination involves clinical decisions that benefit from medical expertise. Your doctor will review your full medical history, assess whether you have any contraindications (such as previous severe allergic reactions or complement disorders), discuss your individual risk profile, and determine the optimal dosing schedule for your circumstances. If you are on immunosuppressive medication, have a chronic health condition, or are pregnant, these factors directly affect vaccine suitability and require doctor-level assessment.
Our Marylebone clinic provides a calm, private environment for your appointment — a significant difference from queuing in a busy pharmacy. You will be monitored for at least 15 minutes after your injection, with a doctor immediately available should you experience any adverse reaction.
Book Your Doctor-Led Vaccination — WhatsApp Us Now →
Meningitis B Vaccine Cost at The Wellness
Private meningitis B vaccination at The Wellness London starts from £195 per dose. A complete vaccination course requires two doses, bringing the total cost from £390 for the full course. This includes your doctor consultation, the Bexsero vaccine itself, administration, and post-vaccination monitoring.
We use Bexsero, manufactured by GSK, which is the same vaccine used in the NHS childhood immunisation programme and the one currently being deployed in the targeted University of Kent vaccination campaign. It is the most widely used MenB vaccine in the UK, with over five million doses administered to date.
Our pricing reflects the quality of a doctor-led service in central London. Unlike pharmacy-based vaccination services, your appointment at The Wellness includes a comprehensive medical assessment and personalised clinical advice from a GMC-registered physician. For families or groups booking multiple vaccinations, please contact us directly to discuss your requirements.
Important note on availability: Following the March 2026 Kent meningitis outbreak, there is a national shortage of privately available MenB vaccine stock. Many pharmacies and clinics across London and the UK have suspended bookings entirely. We are actively working with suppliers to maintain availability, but stock is limited and we cannot guarantee supply at all times. We strongly recommend contacting us as early as possible to check availability.
Check Current Stock & Book — WhatsApp →
Who Should Get the Meningitis B Vaccine
Meningococcal group B disease can affect anyone, but certain groups face a significantly higher risk. The following individuals should strongly consider private MenB vaccination:
University students and young adults (16–25 years): This age group has the second-highest incidence of meningococcal disease after infants. Students are particularly vulnerable because they live in shared accommodation, socialise in crowded indoor venues, and frequently share drinks and vapes — all of which facilitate transmission. The majority of current university students were born before the NHS MenB programme began in 2015 and are therefore unvaccinated.
Teenagers preparing for university: If your child is heading to university in 2026 or 2027, vaccination before they enter halls of residence provides the strongest protection during their most vulnerable period.
Parents of children born before 2015: The NHS routine MenB vaccination programme only covers children born on or after 1 May 2015. If your child was born before this date, they will not have been vaccinated against meningitis B unless you arranged it privately.
People with certain medical conditions: Individuals with asplenia (absent or non-functioning spleen), sickle cell disease, coeliac disease, or complement disorders are at substantially higher risk and are eligible for NHS vaccination — but if you have not received it, private vaccination ensures you are protected.
Travellers to high-risk regions: Meningococcal disease is endemic in parts of sub-Saharan Africa (the "meningitis belt"), and vaccination may be required or recommended before travel.
Healthcare workers and close contacts: If you work in healthcare settings or have been in close contact with someone diagnosed with meningococcal disease, vaccination provides important protection.
How the Meningitis B Vaccine Works
The Bexsero vaccine works by stimulating your immune system to produce antibodies against four key proteins found on the surface of meningococcal group B bacteria. Unlike earlier meningococcal vaccines that targeted the outer polysaccharide coating of the bacteria, Bexsero targets specific surface proteins — a technological breakthrough that was necessary because the MenB outer coating closely resembles human tissue, making it difficult for the immune system to recognise as a threat.
Bexsero is not a live vaccine, which means it cannot cause meningitis. It contains recombinant proteins produced in a laboratory, combined with outer membrane vesicles (OMVs) from a reference strain of Neisseria meningitidis. These components are adsorbed onto an aluminium hydroxide adjuvant to enhance the immune response.
Clinical data show that Bexsero protects against approximately 88% of meningococcal group B strains circulating in the UK (Meningitis Now, 2026). Real-world evidence from the UK childhood immunisation programme demonstrated a 75% reduction in invasive MenB disease among vaccine-eligible infants over a three-year observation period (European Medicines Agency, 2025). While no vaccine provides 100% protection, vaccination dramatically reduces your risk.
After completing the two-dose course, protection is expected to last for at least three years, although the duration of immunity in adolescents and adults is still being studied. Your doctor at The Wellness will discuss whether a booster dose may be appropriate for your circumstances in the future.
What to Expect During Your Appointment
Your meningitis B vaccination appointment at The Wellness London typically takes around 30 minutes and follows a straightforward process.
Your doctor will begin with a brief medical consultation, reviewing your medical history, current medications, and any previous adverse reactions to vaccines. This is an important step — Bexsero should not be given to anyone who has had a severe allergic reaction to a previous dose or to any of its components. Your doctor will also assess whether you need the standard two-dose or the accelerated three-dose schedule based on your risk profile.
The vaccine is administered as a 0.5ml intramuscular injection into the upper arm. You may experience some discomfort at the injection site, which typically resolves within a day or two.
Following your injection, you will be asked to remain in the clinic for at least 15 minutes so that your doctor can monitor you for any immediate adverse reactions, including the rare possibility of anaphylaxis. Common side effects include pain, redness, or swelling at the injection site, fatigue, headache, nausea, and muscle pain. These are generally mild and short-lived, resolving within 24–48 hours.
Your second dose will be scheduled at least one month after the first. We will send you a reminder and can arrange your follow-up appointment at a time that suits you.
Book Your Appointment Now — WhatsApp →
The 2026 Kent Meningitis Outbreak: Why Vaccination Demand Has Surged
The urgency around meningitis B vaccination has intensified dramatically following the outbreak of invasive meningococcal disease in Canterbury, Kent, which began on 13 March 2026. As of 18 March 2026, the UK Health Security Agency (UKHSA) has reported 20 cases under investigation, with nine laboratory-confirmed and six confirmed as the MenB strain. Tragically, two young people have died.
The Health Secretary, Wes Streeting, described the outbreak as "unprecedented" during a statement to the House of Commons on 17 March 2026, and the Deputy Chief Medical Officer called it "the quickest-growing outbreak I've ever seen in my career." The outbreak has been linked to the Club Chemistry nightclub in Canterbury and the University of Kent student community, with cases also reported in London and France.
In response, UKHSA has begun a targeted vaccination programme for approximately 5,000 students living in halls of residence at the University of Kent's Canterbury campus, and over 2,500 doses of preventative antibiotics have been distributed. GPs across the country have been instructed to prescribe antibiotics to anyone who visited Club Chemistry between 5–7 March.
This outbreak has understandably prompted a surge in demand for private MenB vaccination across the UK. A National Pharmacy Association survey of 300 pharmacies found that 87% have seen "considerable" increases in vaccine requests, far exceeding available supply. Many major pharmacy chains, including Boots and Superdrug, have either implemented waiting lists or are completely out of stock.
The Wellness London is working to maintain vaccine availability for our patients, but we strongly advise contacting us promptly to check current stock. In a shortage environment, supply is allocated on a first-come basis and cannot be guaranteed.
Check Availability Immediately — WhatsApp →
Meningitis B Vaccine vs MenACWY Vaccine: Understanding the Difference
It is important to understand that there are multiple types of meningococcal vaccine, and they protect against different strains. The two main vaccines available in the UK are the MenB vaccine (Bexsero) and the MenACWY vaccine.
The MenACWY vaccine protects against meningococcal groups A, C, W, and Y. It has been offered to teenagers as part of the routine NHS immunisation schedule since 2015 and is available up to the age of 25 for those entering university. Many current students will have received this vaccine.
However, MenACWY does not protect against meningococcal group B, which is the strain confirmed in the Kent outbreak and the most common cause of bacterial meningitis in the UK. The MenB vaccine (Bexsero) specifically targets group B and has only been available on the NHS for infants born since 2015 — meaning the vast majority of teenagers, students, and adults remain unprotected.
If you have already received the MenACWY vaccine, you are still not protected against MenB and should consider private vaccination with Bexsero. Both vaccines can be given at the same time if needed, and there is no interaction between them.
Frequently Asked Questions
How much does the meningitis B vaccine cost privately in London?
At The Wellness, the private meningitis B vaccine starts from £195 per dose. A full course requires two doses, totalling from £390. This includes a doctor-led consultation, the Bexsero vaccine, administration, and 15 minutes of post-vaccination monitoring.
Who should get the meningitis B vaccine?
Anyone not previously vaccinated against MenB should consider it, particularly university students, teenagers, young adults aged 16–25, people in shared accommodation, travellers to high-risk regions, and those with specific medical conditions such as asplenia or complement disorders.
Is the meningitis B vaccine available right now?
There is currently a national shortage of privately available MenB vaccine in the UK following the March 2026 Kent outbreak. The Wellness London is actively working to maintain supply. Contact us on WhatsApp (+44 7961 280835) or email team@thewellnesslondon.com to check current availability.
How many doses do I need?
Adults and children aged 11 and over require two doses of Bexsero, given at least one month apart. For optimal protection, the recommended schedule is 0 and 6 months. An accelerated three-dose schedule (0, 1–2, and 6 months) is available for those who need faster protection.
How effective is the meningitis B vaccine?
Bexsero protects against approximately 88% of MenB strains in the UK. The UK childhood immunisation programme recorded a 75% reduction in invasive MenB disease in vaccinated children over three years (EMA, 2025).
What are the side effects?
Common side effects include pain, redness, or swelling at the injection site, fatigue, headache, nausea, and muscle pain. These are typically mild and resolve within 24–48 hours. Serious adverse reactions are very rare.
Can I get the meningitis B vaccine on the NHS?
Currently, the NHS only provides MenB vaccination free of charge for infants (born since 2015) and individuals with certain high-risk medical conditions. Most adults, teenagers, and university students must access the vaccine privately.
The Wellness London is a private healthcare group providing doctor-led medical services from our Marylebone clinic. All vaccinations are administered by GMC-registered doctors. For meningitis B vaccine enquiries, contact us on WhatsApp at +44 7961 280835 or email team@thewellnesslondon.com.
This article is for informational purposes only and does not constitute medical advice. If you believe you have symptoms of meningitis or septicaemia, call 999 or go to your nearest Accident and Emergency department immediately.
References
UK Health Security Agency. Cases of invasive meningococcal disease notified in Kent. GOV.UK. Published 15 March 2026. Updated 18 March 2026.
European Medicines Agency. Bexsero — European Public Assessment Report. EMA. Updated 2025.
Meningitis Now. FAQs on the MenB vaccine (Bexsero). Updated 2026.
Streeting W. Secretary of State update to the House on meningitis outbreak. GOV.UK. 17 March 2026.
CDC/ACIP. New dosing interval and schedule for the Bexsero MenB-4C vaccine. MMWR. December 2024.
GSK. Bexsero Summary of Product Characteristics. Electronic Medicines Compendium. 2025.
